News
Risk-Benefit Analysis of Fisetin as a Senolytic Therapy
- 09/18/2019
The Forever Healthy Foundation announces the public launch of the Risk-Benefit Analysis of Fisetin as a Senolytic Therapy, a systematic review of the published evidence.
It is the second publication of Forever Healthy’s “Rejuvenation Now” initiative following the Risk & Benefit Analysis of NAD+ Restoration Therapy.
About the “Rejuvenation Now” Initiative
Senolytics, NAD+, Lipid Replacement, Decalcification, mTOR Inhibitors, Geroprotectors, … – the first generation of human rejuvenation therapies is available today. However, the field is still very young and the information often spotty. New therapies are emerging, and existing ones are updated or replaced presenting a real challenge for those who want to take advantage of this exciting development as soon as possible.
To overcome this, Forever Healthy’s “Rejuvenation Now” initiative seeks to continuously identify rejuvenation therapies that are available right now and systematically evaluates them on their risks, benefits, procedures and potential application in order to create transparency regarding the current state of said therapies.
Upcoming work of the initiative will cover topics such as the use of essential phospholipids to rejuvenate cell membranes and improve their condition, the use of low-level light therapy to rejuvenate the skin, and the use of EDTA to decalcify both arteries as well as the capillary system.
Coverage at Undoing Aging 2020
For a first, the Undoing Aging conference in 2020 will feature a special “Rejuvenation Now” session highlighting the first generation of human rejuvenation therapies that are either currently in clinical trials or are available today – including risk mitigation strategies and practical application.